Introduction
The human PTEN tumor suppressor gene was isolated based on its localization to chromosome 10q23, a region frequently deleted in multiple types of human cancer Li and Sun, 1997; Steck et al., 1997) . Inactivation of the human PTEN tumor suppressor gene is the underlying cause of the familial Cowden disease syndrome (review by Eng and Peacocke, 1998) . As expected, inactivating lesions in the PTEN gene are frequently found in multiple tumor types including brain, breast, prostate, endometrial, and skin carcinomas Li and Sun, 1997; Steck et al., 1997) . Disruptions of PTEN in mice have been shown to result in early embryonic lethality, while animals heterozygote for this allele develop a broad spectrum of tumors (Di Cristofano et al., 1998; Stambolic et al., 1998; Podsypanina et al., 1999) . These observations establish PTEN as a bona ®de tumor suppressor gene in multiple target organs.
Structurally, PTEN encodes a protein of a predicted molecular mass of *47.1 kDa with an extensive sequence similarity to protein tyrosine phosphatases and the structural protein tensin (reviewed by Maehama and Dixon, 1999) . Biochemically, Maehama and Dixon (1998) have provided evidence that PTEN is highly eective in dephosphorylating the D3-phosphate group of the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate (Ptd-Ins(3,4,5)P 3 ). This ®nding implies that PTEN could serve as a negative regulator of the signaling events mediated by phosphatidylinositol 3-kinase (PI3-K). Indeed, tumor cells harboring a catalytically inactive PTEN result in the constitutive activation of one of the downstream substrates of PI3-K, Akt, which has been extensively implicated in cell survival (Franke et al., 1995) . Consistent with these observations, ectopic expression of wild-type PTEN in various cell types has been demonstrated to exert inhibitory eects on several known biological actions of PI3-K, such as proliferation, cytoskeletal organization, and cell survival (reviewed by Cantley and Neel, 1999) .
Numerous surveys of primary tumors have identi®ed frequent PTEN mutations in exon 5 which contains the core phosphatase catalytic domain (reviewed by Myers and Tonks, 1997; Parson, 1998) . As expected, alterations in the conserved cysteine residue (C129) in this region completely abolishes the ability of PTEN to serve as a lipid phosphatase and to suppress the growth of several glioblastoma cell lines. These ®ndings strongly suggest that the lipid phosphatase activity of PTEN is required for its tumor suppressor function. Intriguingly, mutations outside this catalytic domain have also been reported. These are represented by premature terminations or codon substitutions in the carboxyl terminal 100 amino acid region of the PTEN protein. Although the importance of the C-terminal region to PTEN function is not clear, the presence of a consensus sequence for PDZ-binding domain tends to argue for its role in protein-protein interaction (Songyang et al., 1997) .
Among various human tumors being examined, the frequency of PTEN mutations in human endometrial tumors has been reported to be as high as 55% (Tashiro et al., 1997b; Risinger et al., 1997; Obata et al., 1998) . These lesions are con®ned to the more benign endometrioid type, which is associated with frequent mutations of the Ras oncogenes . This is in contrast to the more malignant carcinoma form of the disease which is associated with p53 and not Ras mutations (Tashiro et al., 1997a) . The apparent co-existence of Ras and PTEN alterations in the same tumor type raises the possibility that they may together contribute to the genesis of endometrial cancer. Indeed, Ras has been shown to bind and activate the 110-kDa alphasubunit of PI3-K (Rodriguez-Viciana et al., 1994) . In this study, we report the eective suppression of Ras transformation by PTEN, and we have de®ned the minimal region in PTEN protein which is required for this novel activity.
Results

Spectrum of PTEN mutations in human endometrial tumors
A survey of the published data for PTEN mutations in human endometrial cancer has revealed that a majority of these alterations were con®ned to the core phosphatase domain around codon 121 ± 129 of exon 5 (Tashiro et al., 1997b; Risinger et al., 1997 Risinger et al., , 1998 Maxwell et al., 1998; Obata et al., 1998) . A signi®cant fraction was, however, found outside this region. Of particular interest was a cluster of missense mutations near codon 173 in the carboxyl side of the core phosphatase catalytic domain. In addition, numerous premature terminations in the carboxyl-terminal region around codon 323 were also observed ( Figure 1a) . To investigate the eects these mutations have on the wildtype PTEN protein, a panel of PTEN mutants was generated. These include three carboxyl terminal truncation mutants with deletions of 4, 33, and 68 amino acids. These mutants were constructed in both wild-type (PTEN-D4, D33, D68) and catalytic-defective (PTEN-AA D4, D33, D68) PTEN cDNA backbone (Figure 1b) . For the region just outside the catalytic core, we selected to generate a mutant with substitution at codon 173 from an arginine to a cysteine residue (PTEN-C173) which accounted for *70% of the missense mutations found at this position in multiple tumors.
Phosphatase activity of various PTEN mutants
To investigate the biochemical properties of various PTEN mutants, cDNA sequences representing individual mutants were ®rst fused in-frame to Glutathione-S-transferase (GST) for the expression of recombinant proteins in E. coli (Figure 2a ). Anity puri®ed GSTfusion proteins were then tested in phosphatase assays using 3 H-labeled inositol [1, 3, 4, 5] -tetrakisphosphate as a substrate. As have been reported previously, we observed a readily detectable phosphatase activity associated with the bacterially expressed wild-type PTEN protein with a speci®c activity of *20.0 pmol/ min/mg (Figure 2b) . Deletions of the C-terminal 4 and 33 amino acids, however, partially dampened the ability of PTEN to dephosphorylate inositol phosphates by 20 and 45%, respectively. The deletion of 68 amino acids, however, resulted in the complete loss of PTEN phosphatase activity similar to that displayed by the catalytic-defective mutant, PTEN-AA. In addition, the substitution of the arginine residue at codon 173 with a cysteine also abolished the phosphatase activity of PTEN. Finally, similar results were obtained when in vitro phosphatase assays were performed using the phosphorylated protein-substrate, poly-Glu4Tyr1 (data not shown).
Suppression of Ras transformation by PTEN
As mentioned earlier, PTEN inactivation and Ras oncogene activation seemed to coexist in human endometrial cancer. To address the potential interaction between Ras oncogene and PTEN tumor suppressor gene, we tested if PTEN could inhibit Ras oncogenicity by focus forming assays. As shown in Figure 3 , when transformation assays were performed in NIH3T3 cells, we observed a dose-dependent suppression of H-Ras R12 transformation with halfmaximal inhibition achieved when a *tenfold molar excess of wild-type PTEN DNA was used. The observed inhibition was unlikely to be due to the cytotoxic eects of PTEN since there was no signi®cant reduction in the number of colonies formed in parallel marker-selected cultures. However, there was a general decrease in the colony size suggesting that the observed anti-Ras activity may be due to the growth suppressive action of PTEN (data not shown). As expected, the catalytic inactive mutant, PTEN-AA , has a greatly reduced ability to suppress H-Ras R12 transforming activity when assays were performed under similar experimental conditions (Figure 4a ).
To de®ne the minimal region of PTEN required for this activity, we tested the ability of various PTEN mutants to inhibit the focus-forming ability of the HRas R12 oncogene in NIH3T3 cells. As shown in Figure 4a , the deletions of the putative PDZ-binding domain (PTEN-D4) or the 33 amino acids (PTEN-D33) in the C-terminus resulted in the progressive loss of anti-Ras activity from 87 to 81 and 72%, respectively. The inhibitory eects of these two mutants were further reduced by introducing two single point mutations in the conserved residues at position Aspartate 92 and Cysteine 124 (PTEN-AAD4, PTEN-AAD33) within the phosphatase catalytic domain. The mutant with truncation of up to 68 amino acids (PTEN-D68) could only block H-Ras transformation by 30%. As expected, the catalytically inactive PTEN-C173 mutant did not signi®cantly perturb the oncogenicity of H-Ras R12.
Next, we performed soft agar assays using marker selected mass cultures of NIH3T3 cells co-transfected with H-Ras R12 and various PTEN mutants. In general, the relative ability of dierent PTEN mutants in suppressing anchorage-independent growth correlated well with their capacity to block focus formation (Figure 4b ). Based on all these data, we conclude that PTEN eciently suppresses the oncogenic eects of Ras in NIH3T3 cells and that this activity is dependent on its phosphatase activity.
Ability of PTEN mutants to suppress the growth of glioblastoma cells
Since similar mutations outside the core catalytic domain were also found in several tumor types including glioblastomas, we tested the eects of expressing these mutants in the U87MG glioblastoma cell line which harbors a defective allele of PTEN gene (Furnari et al., 1997; Cheney et al., 1998; Myers et al., 1998; Li and Sun, 1998) . For these experiments, we introduced all mutants in U87MG cell by retroviral mediated gene transfer. Following infection, cultures were subjected to selection in puromycin-containing medium for 10 days, and the number of continuously proliferating colonies of more than 100 cells were counted. As shown in Figure  5 , the relative ability of dierent PTEN non-catalytic mutants to suppress proliferation of U87MG cells correlated well with their propensity to suppress HRas R12. Although the wild-type PTEN infected cultures showed a similar number of colonies as compared to control plate, they were mostly composed of less than ten slowly proliferating cells ( Figure 5 ).
Perturbation of Ras downstream signaling pathways by PTEN
Two major intracellular kinase cascades have been shown to be important for Ras oncogenicity, and they are the MAPK and PI3-K -dependent signaling pathways (reviewed by Vojtek et al., 1998) . To investigate if PTEN could aect the ability of Ras to stimulate the MAPK cascade, transient kinase assays were performed in NIH3T3 cells. To increase the sensitivity of these assays, an hemagglutinnin (HA)-tagged MAPK/erk2 was co-transfected together with PTEN and Ras. As shown in Figure 6 , Ras routinely stimulated MAPK/erk2 kinase activity by sixfold. Cotransfection of either the wild-type or catalytic inactive version of PTEN partially inhibited the MAPK/erk2 activity by an average of 28%. Since this apparent inhibition was phosphatase-independent, it is therefore most likely to be non-speci®c in nature.
Overexpression of PTEN in vivo has been shown to dampen the kinase activity of a downstream kinase of PI3-K, Akt (Haas-Kogan et al., 1998; Stambolic et al., 1998; Wu et al., 1998; Ramaswamy et al., 1999) . On the contrary, Ras binds and activates the 110 kDa catalytic subunit of PI3-K and this in turn leads to the activation of Akt (Rodriguez-Viciana et al., 1994; Datta et al., 1996) . To test if PTEN could perturb the ability of Ras to activate Akt, we performed transient kinase assays in NIH3T3 cells. Tashiro et al., 1997b; Risinger et al., 1997 Risinger et al., , 1998 Maxwell et al., 1998; Obata et al., 1998) . Closed circles represent missense mutation while opened circles depict nonsense mutation derived from small deletions or point mutations. (b) Schematic representation of PTEN mutants used in this study. The phosphatase (shaded), Tensin homology (shaded and ®lled) and putative PDZ-binding (striped) domains are indicated. Conserved residues critical for PTEN phosphatase activity at codon 92 and 124; and codon 173 in the Tensin homology region are shown To enhance the sensitivity in detecting Akt activation, a HA-tagged Akt construct was co-transfected together with Ras and PTEN. In addition, we found that the activation status of Akt could be more sensitively monitored by an antibody generated against the phosphorylated active form of this kinase. As shown in Figure 7 , transfection of Ras alone produced a *20-fold accumulation of the phosphorylated form of Akt, and the co-expression of PTEN eectively reduced this stimulation to the background level. In contrast, the catalytic inactive PTEN mutant, PTEN-AA not only did not dampen the ability of Ras to activate Akt, it in fact promoted this activity by *1.5-fold. We conclude from these results that the ability of PTEN to inhibit Ras transformation correlates with its propensity to suppress the PI3-K but not the MAPK pathway.
PTEN C-terminus is important for its high levels of ectopic expression in mammalian cells
To ascertain if the anti-Ras activity of various PTEN mutants correlated with their relative ability to inhibit the PI3-K4Akt signaling pathway, we sought to perform transient immune-complex kinase assays in 293T cells. This cell line allowed the expression of high levels of protein and that kinase activity could be measured with enhanced sensitivity. Since we found that exogenously expressed HA-Akt in 293T cells retained considerable basal level of kinase activity even under low serum conditions, various PTEN mutants were co-transfected with HA-Akt. Accordingly, HAAkt was ®rst immunoprecipitated from total cell extracts and its kinase activity was measured using histone 2B (H2B) as a substrate. We observed that wild-type PTEN displayed a *90% suppression of the Akt kinase activity while the catalytic inactive PTEN-AA mutant was defective in the same experiment (Figure 8a ). For the C-terminal truncation mutants, while the PTEN-D4 and PTEN-D33 mutants were both eective in down-regulating the kinase activity of Akt, Figure 2 Phosphatase activity of PTEN mutants. (a) Individual PTEN mutants were fused to GST and expressed in E. Coli. GST-PTEN fusion products were ainity absorbed onto glutatione beads, eluted, and around 1 ± 5 mg of the fusion products were resolved on a 10% SDS ± PAGE gel. The arrows indicate the positions of dierent GST-PTEN fusion proteins stained with Coomassie Blue. Additional bands are most likely to be copuri®ed bacterial protein species. (b) Phosphatase assays were performed using approximately 1 mg of each GST-PTEN fusion protein and with 3 H-labeled inositol (1,3,4,5) tetrakisphosphate as the substrate. Dephosphorylated products were resolved and eluted from AG1-X8 column and counted. Results represent the mean+standard deviation of triplicate measurements derived from a typical experiment which has been repeated once with very similar results being obtained. further truncation, as represented by the PTEN-D68 mutant, nearly abolished this inhibitory eect. As expected, the phosphatase-defective mutants, PTEN-AAD4 and PTEN-AAD33, were nearly inactive in the same assay. Unexpectedly, the PTEN-C173 mutant, although catalytically inactive in vitro, was still capable of suppressing Akt kinase activity by *70% when assays were performed under similar experimental conditions (Figure 8a, left panel) . This apparent residual phosphatase activity was completely abrogated when the C173 mutation was constructed in the PTEN-AA backbone (Figure 8a, right panel) .
Next, we examined the levels of all mutants using an anti-AU5 monoclonal antibody. As shown in Figure  8c , while the PTEN-WT, PTEN-D4, PTEN-AA, and PTEN-AAD4 mutants were all expressed to a similar level, a substantial reduction in protein expression was observed for the PTEN-D33 and PTEN-D68 mutants. In addition, the PTEN-C173 mutant also showed a 28-fold lower level of expression when compared to the wild-type PTEN gene product. Interestingly, the catalytically inactive PTEN-AAD33 mutant, was expressed at a much higher level than its phosphatase active counterpart. Finally, we sought to reproduce these data in a dierent cell system. For this, NIH3T3 cells were transiently transfected with selected PTEN mutants and the relative level of PTEN protein was quanti®ed. As shown in Figure 8b (upper panel), considerably lower levels of protein expression were observed for both PTEN-D33 and -D68 mutants when once again compared to the wild-type counterpart. However, we did not observe a marked reduction in the expression of PTEN-C173 mutant in this case. These dierences were unlikely to be the result of mRNA instability, since Northern blot analysis of total RNA prepared from parallel plates revealed similar levels of PTEN transcripts among dierent transfectants (Figure 8b, lower panel) . Based on all these (a) Focus forming assays were performed in NIH3T3 cells in triplicate by co-transfecting H-Ras R12 mutant (60 ng) with either 2 mg of control vector (Ctr), or various PTEN mutants by the standard calcium phosphate precipitation method. Approximately 2.5 weeks after transfection, cells were ®xed in methanol and stained with Giemsa. Results represent the mean+standard deviation of triplicate samples derived from a typcial experiment and similar assays were performed at least four times. (b) The ability of PTEN mutants to suppress Ras-induced anchorage independent growth was examined by the standard soft-agar assay. Approximately 5610 4 NIH3T3 cells co-transfected with Ras and individual PTEN mutants were suspended in 0.5% of Noble agar. After 3 weeks of incubation, colonies of 41 mm in size were counted. Data represent the mean+standard deviation of triplicate samples derived from a typical experiment and similar assays were performed at least two times Figure 5 Growth suppression of U87MG cells by PTEN mutants. All cDNAs representing dierent PTEN mutants were cloned into the vector, pBabePURO, and were not epitope-tagged. Approximately 10 6 Phoenix packaging cells were transfected with 3 mg of each expression plasmid. Retroviral particles in the supernatant were collected and titered on NIH3T3 cells. Similar titer of retroviral particles of each PTEN mutant were used to infect 4610 5 U87MG cells in the presence of polybrene. Following selection in puromycin for 10 days, colonies were stained with Giemsa and counted. Data represents the mean+ standard deviation of triplicate samples derived from a typical experiment which has been repeated once (upper panel). The marked suppression of proliferation by wild-type PTEN is indicated in the lower panel results, we conclude that the relative ability of dierent PTEN mutants to inhibit Ras transformation correlates with their propensity to inhibit Akt kinase activity. In addition, deletion of 33 amino acids or more in PTEN C-terminus leads to a reduction of its protein level in ectopic expression system.
Discussion
The knowledge derived from the present study can be of threefold. First, the PTEN tumor suppressor gene eectively blocks cellular transformation caused by the Ras oncogene. Second, the C-terminal 33 amino acid region of PTEN is not critical for its catalytic activity. It is also not absolutely required for suppressing Ras transformation or inhibiting the growth of U87MG cells. Third, the C-terminal sequence of PTEN may be involved in the maintenance of wild-type PTEN protein integrity.
The ability of PTEN to suppress Ras transformation is interesting. Our ®ndings raise the possibility that precursor lesions in endometrium harboring Ras mutations may acquire growth advantage by selectively inactivating the wild-type PTEN allele. However, it is at present not known whether Ras and PTEN mutations are mutually exclusive, or that Ras activation precedes PTEN inactivation. Biologically, it has been demonstrated that PI3-K pathway plays a pivotal role in Ras transformation (Rodriguez-Viciana et al., 1997). In fact, a dominant negative mutant of PI3-K, p85 DiSH2-N, is also capable of suppressing Ras to a similar extent as the wild-type PTEN allele (RodriguezViciana et al., 1997). Although our data suggests that the inhibition of Akt kinase activity by PTEN correlates well with the suppression of Ras oncogenicity, the role of Akt in Ras transformation is not fully de®ned. Akt has been demonstrated to play an important role in cell survival, its eect on growth control is by far unclear. More recently, a constitutively active Akt has been shown to rescue G1 cell cycle arrest caused by expressing PTEN in a glioblastoma cell line (Ramaswamy et al., 1999) . Other plausible candidates that could also be inhibited by PTEN are the RHO gene family members, such as Rac and Cdc42. In fact, these two GTPases have been shown to be downstream substrates of PI3-K (Tang et Figure 6 The eect of PTEN on Ras-induced MAPK activity. Transient MAPK assays were performed in NIH3T3 cells by cotransfecting the indicated plasmids together with an HA-erk2 construct. Kinase reactions were performed on HA-erk2 immunoprecipitates in the presence of [g-32 P]ATP with myelin basic protein (MBP) as a substrate. Phosphorylated MBP (kinase) was resolved on a 15% SDS ± PAGE, dried, and exposed to X-ray ®lms. Data represents the mean+standard deviation of triplicate samples derived from a typical experiment which has been repeated twice (upper panel). The expression levels of HA-erk2, H-Ras R12 and AU5-PTEN, were detected by Western blot (WB) analysis using the antibodies indicated Figure 7 The eects of PTEN on Ras-induced Akt kinase activity. Transient Akt kinase assays were performed in NIH3T3 cells by co-transfecting the indicated plasmids together with an HA-Akt construct. Following transfection, HA-Akt was immunoprecipitated using an anti-HA monoclonal antibody and resolved on a 12.5% SDS ± PAGE. The extent of the phosphorylation of HA-Akt (P-AKT) was examined by a polyclonal antibody directed against the phosphorylated threonine residue at position 308 of Akt. Data represents the mean+standard deviation of triplicate samples derived from a typical experiment which has been repeated twice (upper panel). The expression levels of HA-Akt, H-Ras R12, and AU5-PTEN, were detected by Western blot (WB) analysis using the indicated antibodies (lower panels) al., 1999), and their active mutants have been implicated in tumor invasion (Michiels et al., 1995; Keely et al., 1997) . It will be of interest to measure the GTP-binding status of Rac and Cdc42 in PTENnegative tumors.
Our data using various C-terminal truncation mutants shows certain similarities to the DPDZ BD mutant reported by Morimoto et al. (1999) , in which deletion of the putative PDZ-binding domain did not result in a loss of phosphatase activity. Indeed, the PTEN-D4 mutant used in the present study is also capable of suppressing Ras transformation and the proliferation of U87MG cells. It is interesting that the DPDZ BD mutant has a greatly diminished ability to block anchorage-independent growth of U373 cells (Morimoto et al., 1999) . It is possible that the Cterminal domain play a crucial role in regulating PTEN tumor suppressor function when cells are cultured under non-adherent conditions. Also, based on the last four amino acid sequence, ITKV, it predicts a putative PDZ-binding domain for the Group I PDZ-containing proteins which include members of the Disc Large Tumor Suppressor gene (Dlg) family (Songyany et al., 1997) . However, whether PTEN mediates binding to Dlg remains to be determined. P]ATP and H2B. Reactions were stopped by the addition of SDS-sample buer and aliquots were resolved on a 15% SDS ± PAGE gel, dried and exposed to X-ray ®lms. The extent of phosphorylation of the H2B is indicated (kinase). The expression levels of HA-Akt and various AU5-PTEN mutants were revealed by Western blot (WB) analysis using anti-HA and -AU5 antibodies, respectively. Data represents the mean+standard deviation of triplicate samples derived from a typical experiment which has been repeated twice. (b) The expression levels of various PTEN mutants were examined by transient transfecting 4.5610 5 NIH3T3 cells with 6.0 mg of each construct. Three days after transfection, parallel plates were processed for protein extracts and total cellular RNA. The expression levels of PTEN mutants were examined by both Western blot (WB) analysis using an anti-PTEN antibody (UBI) (upper panel). Filters were exposed to X-ray ®lms for a short (left panel) or long (right panel) period of time to reveal the PTEN-D33 mutant (arrows) which is located below a non-speci®c band. Northern blot analysis was also carried out using a full length PTEN cDNA as probe (lower panel). The *1.3 kb transcripts of various PTEN mutants are shown. Ethidium bromide stained gel showing the 18S ribosomal RNA is presented in the bottom panel as a control for normalized loading Another interesting ®nding is that the PTEN-D33 and -D68 mutants, which resemble the predicted truncated gene products found in some human tumors, have very low levels of protein expression when ectopically expressed in 293T and NIH3T3 cells. Also, bacterially synthesized GST-PTEN-D33 and D68 fusion proteins are partially active and totally inactive, respectively. We infer from these results that the PTEN-D33 mutant may still retain a partially intact catalytic domain, and although expressed at a lower level due to increased degradation, is sucient to inhibit Ras transformation and Akt kinase activity. In contrast, the PTEN-D68 mutant may be a completely unfolded tertiary structure and therefore is inactive in most of the assays. In support of this hypothesis, Georgescu et al. (1999) have recently identi®ed a bstrand region in PTEN C-terminus that is important for regulating the half-life of this molecule. Based on all these observations, it is highly likely that the increased degradation of PTEN by premature termination may constitute a novel mechanism responsible for its loss of tumor suppressor function in human cancer.
Our data with the PTEN-C173 mutant may explain the frequent mutation of this codon in a wide variety of tumors. However, we cannot explain why the PTEN-C173 mutant is still capable of suppressing Akt kinase activity even though it is defective in in vitro phosphatase assays. In fact, this data is reproducible with an independent DNA preparation and that this mutant when constructed in the catalytic inactive PTEN-AA backbone fails to suppress Akt. One possible explanation is that although greatly attenuated, PTEN-C173 may still possess residual phosphatase activity, and this eect is registered in an overexpression system. Alternatively, PTEN may have phosphatase activity towards a speci®c isoform of inositide not being examined in our in vitro phosphatase assays. In summary, we have demonstrated that PTEN has a potent inhibitory eect on the Ras oncogene and a more detailed delineation of the mechanisms involved will be necessary. Also, by understanding the regulation and eventual enhancement of PTEN protein stability in human tumors may lead to novel revenues for therapeutic intervention.
Materials and methods
Cell lines
The NIH3T3 cell line was maintained in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% calf serum (CS). The U87MG and 293T cell lines were maintained in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
Infection of U87MG glioblastoma
For proliferation studies in U87MG cells, individual PTEN mutant cDNAs were ®rst cloned into the retroviral vector, pBabepuro, and 5 mg of each construct was transfected into the packaging cell line, Phoenix. Retroviral particles were collected and titered on NIH3T3 cells by selecting in medium containing 2 mg/ml of puromycin. For standard infection, *10 5 viral particles were incubated with 1.5610 5 U87MG cells on 60-mm plate in a ®nal volume of 2 ml in the presence of polybrene (4 mg/ml) for 5 h. Infected cells were then subjected to selection in 1.5 mg/ml of puromycin and the number of drug resistance colonies was visualized by staining with Giemsa and then counted.
Plasmids
The activated H-Ras R12 mutant was cloned in the expression vector, pCEV29 (Osada et al., 1999) . The PTEN wild-type (PTEN-WT) and catalytic-inactive (PTEN-AA) cDNAs have previously been described . For the generation of PTEN C-terminal truncation mutants, termination codons were introduced at positions 336, 371, and 400 of both PTEN-WT and -AA cDNAs by PCR-based site-directed mutagenesis. For the generation of the PTEN-C173 mutant, we employed a similar PCR-based mutagenesis protocol by using the following complementary primer pair: 5'-ACTATTCCCAGTCAGAGGTGCTATG-TGTATTATTATAGC-3' (forward), 5'-GCTATAATAATA-CACATAGCACCTCTGACTGGGAATAGT-3' (reverse), where the underlined residues depict the arginine to cysteine substitution at this position. All ampli®ed products were restriction digested with BamHI and EcoRI enzymes, and fused in-frame in the N-terminal to an AU5-epitope tag present in the expression vector, pCEFL KZ AU5 (Crespo et al., 1997) . The authenticity of all constructs were con®rmed by sequencing analysis. Expression plasmids used in transient immune-complex kinase assays included the pLTR-HA-erk2 (Coso et al., 1995) , and CMV5-HA-Akt (Franke et al., 1995) , which have all been described previously.
Antibodies
The anti-HA and anti-Ras (Y13-259) monoclonal antibodies were derived from the Monoclonal Core Facility of the Mount Sinai School of Medicine. The anti-PTEN polyclonal antibody (UBI), the anti-AU5 monoclonal antibody (Covance) and the anti-phospho-Akt polyclonal antibody (NEB) were purchased from commercial sources.
Phosphatase assays
Selected PTEN mutants were ®rst fused to GST by cloning into the prokaryotic expression vector pGEXKG (Guan and Dixon, 1991) , and fusion proteins were anity puri®ed as previously described with minor modi®cations (Maehama and Dixon, 1998) . For phosphatase assays, approximately 1 mg of GST-fusion protein was used in a 20 ml reaction containing 100 mM Tris-HCl (pH 8.0), 10 mM DTT, 0.02 mCi of 3 H-labeled inositol (1,3,4,5) tetrakisphosphate (New England Nuclear) for 30 min at 378C. Dephosphorylated products were puri®ed on a 0.5 ml AG1-X8 column (Biorad), eluted with 5 ml of 0.7 M HCOOH NH 4 /0.1 M HCOOH, and 1 ml of the eluent was counted on a scintillation counter.
Transformation assays in NIH3T3 cells
Approximately 1.5610 5 NIH3T3 cells were plated onto a 100-mm culture dish and DNA transfection was performed by the standard calcium phosphate precipitation method (Wigler et al., 1977) . After transfection, cells were medium changed twice a week with DMEM containing 5% CS and the number and quality of foci were scored every week for up to 3 weeks. All plates were then ®xed in 70% methanol and stained with Giemsa solution for further quanti®cation. For proliferation in semi-solid agar, cells transfected with Ras and PTEN in dierent selectable markers were co-selected with puromycin (1.0 mg/ml) and G418 (750 mg/ml) for 7 days, and *5610 4 cells of the mass cultures were resuspended in 0.5% Noble agar (Difco). After 3 weeks in culture, progressively growing colonies were stained with a solution of 1 mg/ml of p-iodonitrotetrazonium violet (Sigma).
Immunoprecipitation and Western blot analysis
Unless otherwise stated, all cell solubilization steps were performed using the standard RIPA buer. For immunoprecipitation, usually 1 mg of a monoclonal antibody was added to *500 mg of total cell extracts, incubated at 48C for 1 h, and then absorbed onto 30 ml of g-bind G sepharose beads (Pharmacia) for an additional 1 h at 48C. Immune complexes were then washed three times with lysis buer and bound proteins were eluted by boiling in Laemmli buer and resolved on SDS ± PAGE gels. For standard Western blot analysis, 100 ± 200 mg of total cell extracts were resolved on SDS ± PAGE instead. Following transfer onto nitrocellulose membranes (Schleicher & Schuell), proteins of interest were detected by the sequential incubation with primary antibodies (1 : 500 ± 1 : 1000 dilution), and visualized by the standard ECL detection method under conditions recommended by the manufacturer (Amersham). Filters were then subjected to autoradiography and the relative intensity of individual bands was quanti®ed by an imaging densitometer (Biorad).
Transient MAPK assay
For transient assays, 1610 6 NIH3T3 cells were transfected by standard calcium phosphate precipitation method with 0.8 mg of an HA-epitope-tagged erk2, 2 mg of H-Ras R12, and 5 mg of dierent PTEN mutants (Coso et al., 1995) . Approximately 12 h after transfection, cells were placed in serum-depleted medium for 18 h and then solubilized in 600 ml of 20 mM HEPES (pH 7.5), 2.5 mM MgCl 2 , 10 mM EGTA (pH 8.0), 1% NP-40, 40 mM b-glycerophosphate, 2 mM Na 3 VO 4 , 2 mM leupeptin, 2 mM aprotinin, and 1 mM PMSF. Exogenously expressed HA-MAPK/erk2 was immunoprecipitated from total cell lysates with 1 mg of an anti-HA monoclonal antibody coupled to 30 ml of g bind G-sepharose beads (Pharmacia). Immune complexes were washed three times with 1% NP-40 and 2 mM Na 3 VO 4 in PBS, one time with 0.5 mM LiCl and 100 mM Tris-HCl (pH 7.5), and one time in kinase buer (see below). G-sepharose beads were then resuspended in 30 ml of kinase reaction buer containing 12.5 mM MOPS (pH 7.5), 12.5 mM b-glycerophosphate, 7.5 mM MgCl 2 , 0.5 mM EGTA, 0.5 mM NaF, 0.5 mM Na 3 VO 4 , 1 mCi of [g-32 P]ATP, 20 mM ATP, 3.3 mM DTT, and 60 mg of myelin basic protein (Sigma). Following incubation at 308C for 30 min, 60 ml of 26 Laemmli buer was added to stop the reactions. Approximately 20 ml of the solubilized materials were then resolved on a 14% SDS ± PAGE, dried, and exposed to X-ray ®lms at 7708C.
Transient Akt kinase assay
Approximately 5610 5 293T cells were transfected with 2 mg of CMV5-HA-Akt and 5 mg of dierent PTEN mutants (Franke et al., 1995) . About 12 h after transfection, cultures were serum-starved for 18 h and solubilized in a buer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 1% NP-40, 10 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 3 P 3 O 4 , 1 mM EDTA, 1 mM PMSF, 2 mM leupeptin, and 2 mM aprotinin. Exogenously expressed HA-Akt was immunoprecipitated with 1 mg of an anti-HA monoclonal antibody coupled to 30 ml of G-protein sepharose beads (Pharmacia) at 48C for 3 h. Immune complexes were washed three times with lysis buer, once with ice cold water, and once with kinase buer [20 mM HEPES (pH 7.4), 10 mM MnCl 2 , and 10 mM MgCl 2 ]. Kinase reactions were started by adding 30 ml of a mixture containing 1 mM DTT, 5 mM ATP, 20 mCi of [g-32 P]ATP, and 3 mg of histone-2B (H2B; Boehringer Mannheim) in kinase reaction buer. Following incubation at 308C for 30 min, 60 ml of 26 Laemmli buer was added to stop the reactions. Approximately 20 ml of the solubilized materials were then resolved on a 14% SDS ± PAGE gel, dried and exposed to X-ray ®lms at 7708C.
